Total Payments
$1.2M
2024 Payments
$196,894
Companies
33
Transactions
901
Medicare Patients
13,046
Medicare Billing
$14.3M
Payment Breakdown by Category
Consulting$550,808 (46.9%)
Other$547,333 (46.6%)
Travel$45,158 (3.8%)
Food & Beverage$21,995 (1.9%)
Research$8,150 (0.7%)
Education$39.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $550,808 | 196 | 46.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $515,034 | 142 | 43.9% |
| Travel and Lodging | $45,158 | 121 | 3.8% |
| Honoraria | $27,799 | 18 | 2.4% |
| Food and Beverage | $21,995 | 412 | 1.9% |
| Unspecified | $8,150 | 8 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,500 | 3 | 0.4% |
| Education | $39.00 | 1 | 0.0% |
Payments by Type
General
$1.2M
893 transactions
Research
$8,150
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $453,148 | 277 | $0 (2024) |
| Alcon Vision LLC | $170,103 | 122 | $0 (2024) |
| Genentech USA, Inc. | $164,908 | 138 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $71,250 | 54 | $0 (2024) |
| Alcon Laboratories Inc | $61,355 | 40 | $0 (2018) |
| Alcon Research LLC | $44,014 | 18 | $0 (2024) |
| Astellas Pharma US Inc | $24,309 | 24 | $0 (2024) |
| Hoffmann-La Roche Limited | $22,994 | 5 | $0 (2024) |
| Spark Therapeutics, Inc. | $21,335 | 12 | $0 (2019) |
| F. Hoffmann-La Roche AG | $20,299 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $196,894 | 150 | Regeneron Healthcare Solutions, Inc. ($51,315) |
| 2023 | $174,985 | 141 | Genentech USA, Inc. ($52,432) |
| 2022 | $197,153 | 139 | Regeneron Healthcare Solutions, Inc. ($54,635) |
| 2021 | $115,240 | 72 | Regeneron Healthcare Solutions, Inc. ($59,496) |
| 2020 | $112,135 | 64 | Regeneron Healthcare Solutions, Inc. ($68,120) |
| 2019 | $118,761 | 114 | Regeneron Healthcare Solutions, Inc. ($50,751) |
| 2018 | $103,106 | 90 | Regeneron Healthcare Solutions, Inc. ($33,988) |
| 2017 | $155,209 | 131 | Regeneron Healthcare Solutions, Inc. ($92,312) |
All Payment Transactions
901 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,096.20 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $960.00 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 12/28/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/27/2024 | Genentech, Inc. | Lucentis (Biological), Susvimo | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.02 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/17/2024 | Genentech USA, Inc. | Susvimo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/10/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $6.67 | General |
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $4.73 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,360.00 | General |
| 12/05/2024 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alcon Vision LLC | AcrySof (Device), Clareon, AcrySof IQ PanOptix UV IOL | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $12.64 | General |
| 12/03/2024 | Genentech USA, Inc. | Susvimo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/03/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $18.77 | General |
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/21/2024 | Alcon Vision LLC | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,116.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $601.95 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $367.34 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $224.94 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $192.61 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $172.06 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab | F. Hoffmann-La Roche AG | $2,434 | 1 |
| STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | F. Hoffmann-La Roche AG | $2,056 | 2 |
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $1,562 | 1 |
| Refill-Exchange Procedure for the Port Delivery System with Ranibizumab: Optimization and Enhanced Training | F. Hoffmann-La Roche AG | $1,452 | 2 |
| Optimization of the Refill-Exchange Procedure for the Port Delivery System with Ranibizumab | F. Hoffmann-La Roche AG | $451.88 | 1 |
| A PHASE 2, DOUBLE-MASKED, RANDOMIZED, CONTROLLED, MULTIPLE-DOSE, REGIMEN-RANGING STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL REGN2176-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $193.76 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,999 | 33,225 | $6.8M | $3.5M |
| 2022 | 16 | 3,080 | 12,623 | $6.7M | $3.4M |
| 2021 | 18 | 3,277 | 11,735 | $6.8M | $3.6M |
| 2020 | 20 | 3,690 | 12,261 | $6.9M | $3.7M |
Total Patients
13,046
Total Services
69,844
Medicare Billing
$14.3M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 339 | 3,206 | $4.0M | $2.2M | 54.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 79 | 23,040 | $1.2M | $662,286 | 57.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 55 | 954 | $477,000 | $174,766 | 36.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 455 | 1,880 | $498,651 | $167,191 | 33.5% |
| J3490 | Unclassified drugs | Office | 2023 | 30 | 53 | $131,865 | $94,097 | 71.4% |
| 92134 | Imaging of retina | Office | 2023 | 939 | 2,349 | $174,487 | $61,954 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 597 | 885 | $148,982 | $50,104 | 33.6% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 13 | 270 | $44,550 | $32,497 | 72.9% |
| J3590 | Unclassified biologics | Office | 2023 | 28 | 85 | $52,750 | $31,619 | 59.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 184 | 216 | $51,535 | $19,196 | 37.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 17 | 19 | $31,267 | $11,199 | 35.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $24,571 | $8,801 | 35.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 115 | 115 | $24,032 | $8,300 | 34.5% |
| 92250 | Photography of the retina | Office | 2023 | 34 | 39 | $2,670 | $979.44 | 36.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 19 | $1,995 | $676.80 | 33.9% |
| 92133 | Imaging of optic nerve | Office | 2023 | 16 | 16 | $1,060 | $220.11 | 20.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 344 | 3,468 | $4.3M | $2.5M | 56.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 103 | 2,492 | $1.2M | $551,106 | 44.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 474 | 1,907 | $518,357 | $173,723 | 33.5% |
| 92134 | Imaging of retina | Office | 2022 | 1,003 | 2,203 | $166,547 | $58,486 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 621 | 906 | $155,361 | $53,725 | 34.6% |
| J3590 | Unclassified biologics | Office | 2022 | 46 | 127 | $100,500 | $50,151 | 49.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 11 | 1,020 | $51,000 | $30,438 | 59.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 129 | 129 | $40,968 | $14,651 | 35.8% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2022 | 20 | 22 | $36,670 | $14,020 | 38.2% |
About Dr. John Kitchens, M.D
Dr. John Kitchens, M.D is a Ophthalmology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972503993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kitchens, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $196,894 received in 2024. These payments were reported across 901 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($550,808).
As a Medicare-enrolled provider, Kitchens has provided services to 13,046 Medicare beneficiaries, totaling 69,844 services with total Medicare billing of $14.3M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Lexington, KY
- Active Since 08/01/2005
- Last Updated 05/08/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1972503993
Products in Payments
- EYLEA (Biological) $255,806
- Constellation (Device) $145,156
- EYLEA AFLIBERCEPT INJECTION (Biological) $134,347
- EYLEA HD (Biological) $77,075
- NGENUITY (Device) $61,969
- Vabysmo (Drug) $48,253
- SUSVIMO (Drug) $42,349
- Lucentis (Biological) $38,573
- Syfovre (Drug) $31,716
- VABYSMO (Drug) $30,726
- Susvimo (Drug) $26,744
- Izervay (Drug) $24,059
- LUXTURNA (Biological) $21,335
- ILUVIEN (Drug) $18,033
- AcrySof (Device) $12,900
- CNTO 2476 (Biological) $12,670
- YUTIQ (Drug) $9,399
- PAVBLU (Biological) $8,000
- BEOVU (Drug) $6,675
- ForeseeHome (Device) $4,560
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Lexington
Dr. Jeremy Kieval, M.d, M.D
Ophthalmology — Payments: $354,855
Ophthalmology $354,855
Gary Wortz, Md, MD
Ophthalmology — Payments: $195,872
Ophthalmology $195,872
Blake Isernhagen, Md, MD
Ophthalmology — Payments: $188,723
Ophthalmology $188,723
Dr. Bruce Koffler, Md, MD
Ophthalmology — Payments: $100,236
Ophthalmology $100,236
Kunal Kanitkar, M.d, M.D
Ophthalmology — Payments: $75,249
Ophthalmology $75,249
Dr. Miguel Busquets, M.d, M.D
Ophthalmology — Payments: $42,842
Ophthalmology $42,842